loading page

Severe Hemolytic Exacerbations of Chinese PNH Patients infected SARS-CoV-2 Omicron
  • +8
  • Hui Yang,
  • Xingxing Chai,
  • Yuemin Gong,
  • Xinyu Zhang,
  • Lingling Wang,
  • Xin Zhou,
  • Xiaoyu Chen,
  • Jinge Xu,
  • Dan Xu,
  • Jianyong Li,
  • Guangsheng He
Hui Yang
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital
Author Profile
Xingxing Chai
second people’s hospital of Lianyungang
Author Profile
Yuemin Gong
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital
Author Profile
Xinyu Zhang
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital
Author Profile
Lingling Wang
Wuxi People's Hospital
Author Profile
Xin Zhou
Wuxi People's Hospital
Author Profile
Xiaoyu Chen
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital
Author Profile
Jinge Xu
The Second Affiliated Hospital of Xuzhou Medical University
Author Profile
Dan Xu
Funing People's Hospital
Author Profile
Jianyong Li
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital
Author Profile
Guangsheng He
Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital

Corresponding Author:[email protected]

Author Profile

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by hemolytic anemia, bone marrow failure, thrombophilia. COVID-19, caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with many variants including Omicron. This study depicted demographic and clinical characteristics of 20 PNH patients with SARS-Cov2 Omicron infection. All the patients hadn’t previously been administrated with complement inhibitors. They all were with high disease activity (HDA), and LDH level exceeded any documented since the diagnosis of PNH, and those reported in the literature for previously stable treatment with complement inhibitors. D-dimer level elevated in 10 patients. 2 patients developed mild pulmonary artery hypertension. Glomerular filtration rate (GFR) declined in 5 patients. 1 patient developed acute renal failure and underwent hemodialysis. Anemia and hemolysis were improved in 5 patients treated with eculizumab. Hemolytic exacerbation of PNH with COVID-19 is severe and eculizumab may be an effective treatment.
03 Jun 2023Submitted to Immunity, Inflammation and Disease
05 Jun 2023Submission Checks Completed
05 Jun 2023Assigned to Editor
05 Jun 2023Review(s) Completed, Editorial Evaluation Pending
14 Jun 2023Reviewer(s) Assigned
06 Jul 2023Editorial Decision: Revise Minor
17 Jul 20231st Revision Received
19 Jul 2023Submission Checks Completed
19 Jul 2023Assigned to Editor
19 Jul 2023Review(s) Completed, Editorial Evaluation Pending
20 Jul 2023Reviewer(s) Assigned
21 Jul 2023Editorial Decision: Accept